Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved entities : Amneal pharmaceuticals, inc. save search
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -2.64%
fda approval
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval injection
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Published: 2023-07-03 (Crawled : 22:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -2.26%
H: 0.66%
C: 0.66%
xyrem fda authorized approval
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
Published: 2023-06-14 (Crawled : 22:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 2.33%
H: 4.17%
C: 1.14%
rtu fda approval
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
Published: 2022-12-20 (Crawled : 17:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -0.46%
H: 0.47%
C: -2.33%
approval injection
Amneal Receives FDA Approval for Leuprolide Acetate Injection
Published: 2022-11-02 (Crawled : 12:20) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: -10.21%
fda approval injection
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
Published: 2022-06-01 (Crawled : 13:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 6.41%
H: 3.29%
C: 1.37%
lyvispah sclerosis multiple sclerosis
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
Published: 2022-05-31 (Crawled : 21:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
fylnetra biosimilar approval
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
Published: 2022-05-27 (Crawled : 11:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 1.88%
H: 0.71%
C: -1.7%
biosimilar approval
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
Published: 2022-04-18 (Crawled : 20:00) - prnewswire.com
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -0.73%
H: 4.4%
C: 2.69%
alymsys fda biosimilar
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Published: 2022-04-13 (Crawled : 21:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -0.7%
H: 6.46%
C: 1.88%
alymsys approval
Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
Published: 2022-03-02 (Crawled : 19:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -7.42%
H: 1.89%
C: -5.19%
approval bioscience hiv biosimilar
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Published: 2022-03-01 (Crawled : 22:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
approval biosimilar
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Published: 2021-11-19 (Crawled : 14:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -1.31%
H: 4.08%
C: 1.99%
approval ophthalmic emulsion
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
Published: 2021-10-27 (Crawled : 14:15) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: -2.91%
fda approval
Amneal Receives Approval for Generic TobraDex®
Published: 2021-07-19 (Crawled : 21:00) - biospace.com/
AMRX | $5.455 1.58% 330K
|
Health Technology
|
| O: -2.09%
H: 2.37%
C: 2.37%
approval
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.